Sa1229 Infliximab as Second Anti-TNF Agent in Crohn's Disease: Durability and Tolerance of Therapy

Jason E. Gonzaga; Yelena Zadvornova; Dan Joseph Stein; Lilani P. Perera; Amar S. Naik; Nanda Venu

doi:10.1016/s0016-5085(12)60936-6

Related publications

Article2013

Su1239 Mucosal Healing by Individual Anti TNF Agent in Crohn's Disease in Tertiary Care Setting

Zainab Ashir, Corinne Guilday, Yelena Zadvornova, Dan Joseph Stein, Amar S. Naik, Nanda Venu, Kari Best, Susan Skaros, Kia Saeian, Lilani P. Perera

Article2012

Sa1910 Long Term Outcomes of Crohn's Disease Patients on Maintenance Anti-TNF-α Therapy

Lilani P. Perera, Yelena Zadvornova, David G. Binion, Corinne Guilday, Dan Joseph Stein, Amar S. Naik, Nanda Venu, Kari Best, Susan Skaros

Article2009

Impact of prior irregular infliximab dosing on performance of long-term infliximab maintenance therapy in Crohn's disease†

Dan Joseph Stein, Ashwin N. Ananthakrishnan, Mazen Issa, John B. Williams, Dawn B. Beaulieu, Yelena Zadvornova, Anita Ward, Kathryn Johnson, Josh F. Knox, Sue Skaros, David G. Binion

Article2012

Sa1889 10 Year Performance of Anti TNF Biologic Therapy in Inflammatory Bowel Disease

Lilani P. Perera, Yelena Zadvornova, David G. Binion, Corinne Guilday, Dan Joseph Stein, Amar S. Naik, Nanda Venu, Kari Best, Susan Skaros

Article2014

Identification of inflammatory mediators in patients with Crohn's disease unresponsive to anti-TNFα therapy

Raquel Franco Leal, Núria Planell, Radhika Kajekar, Juan José Lozano, Íngrid Ordás, Isabella Dotti, Manel Esteller, Maria Carme Masamunt, Harsukh Parmar, Elena Ricart, Julián Panés, Azucena Salas